Clinical analyzed of pemetrexed combined cisplaton in the treatment of advanced NSCLC
Objective To investigate efficacy and toxicities of pemetrexed in combination with cisplaton in previously treated patients with NSCLC. Methods Select 70 patients, divided into PEM group(35 cases), GP group(35 cases), PEM group: received treaty of pemetrexed 500mg/m2, d1, >10min ivgtt, DDP 75mg/m2 d1, d2, d3; GP group: GEM 1000mg/m2, d1, d8, DDP 75mg/m2, d1, 12, d3. To evaluate efficacy after 2 cycles. Results PEM group: RR were 37.14%. GP group: RR were 31.43%. The main toxicities was the blood toxicity. Conclusion Pemetrexed combined with cisplaton is an ideal option for advanced NSCLC. But in terms of adverse reactions to significantly reduce the incidence of PEM group, tolerance is good, is worth further clinical application.
NETL
NSTL
万方数据
维普
